Compare CMPX & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | BNTC |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.8M | 454.2M |
| IPO Year | 2020 | 2020 |
| Metric | CMPX | BNTC |
|---|---|---|
| Price | $2.15 | $13.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $14.57 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 2.6M | 68.2K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $934.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.61 | $9.85 |
| 52 Week High | $6.88 | $16.76 |
| Indicator | CMPX | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 61.93 |
| Support Level | $1.88 | $11.35 |
| Resistance Level | $2.02 | $13.48 |
| Average True Range (ATR) | 0.11 | 0.69 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 37.33 | 91.24 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.